36KR Holdings (NASDAQ:KRKR) Stock, Quote.Headers.trade-ideas

36KR Holdings

36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.

Trading Charts on a Display

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEON

AMIX

AREB

AVXL

CHGG

CNTM

DATS

GRNQ

GROM

KRKR

MTCH

OPEN

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SIEB

UAVS

Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

movers image

Intraday Update

AAGR

ADTN

ALUR

APLD

ASAN

BNAI

CABA

CDMO

CIFR

CLOV

CRKN

DMTK

GOSS

IPDN

KAVL

MBIO

MINM

MOLN

ORGS

RELI

SHCR

SMTK

SPEC

SRPT

SWBI

TPHS

TREX

WAVE

ZCAR

Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

earnings

Penny Stocks

36Kr Holdings shares are trading higher Friday after the company announced it has entered into a strategic partnership with SenseTime. Here&#39;s a look at what to know: 

Why 36Kr Stock Is Up Today

36Kr Holdings Inc. - American Depositary Shares

36KR Holdings Inc

The Federal Reserve slashed interest rates by half a percentage point on Wednesday, marking the first rate cut in years. The benchmark federal funds rate now ranges<a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead"> between 4.75% and 5%</a>. While nearly half luxury home purchases are made in cash, that rate cut is poised to impact the high-end housing market. Industry experts anticipate a surge in confidence and activity across all property segments, with potential price increases in top-tier real estate.
Don't Miss:
<ul>
<li>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Here's how you can invest in the city before that happens</a>.</li>
<li>During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses. </a></li>
</ul>
President and CEO of Berkshire Hathaway HomeServices EWM Realty in South Florida, Ron Shuffield, views the rate cut positively. "The drop in the Fed rate today is good news for everyone,&#8221; he told Mansion Global. "While high-end buyers often don't have a traditional home mortgage, everyone is impacted by changes in interest rates – whether in their home mortgage, their business financing, their personal life or in lines of credit they roll in and out of – all of which are based on interest rates," Shuffield said.
Trending: Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity at just $500. </a>Lower rates are expected to have the most pronounced impact in the <a href="https://www.benzinga.com/markets/24/09/40916749/think-a-quarter-or-half-point-fed-cut-will-make-homes-more-affordable-just-the-opposite-may-happen-h">middle and lower segments </a>of the housing market, where traditional financing is more common. However, the luxury market is not immune to their effects.
According to Freddie Mac, mortgage rates have already declined, reaching 6.2% as of Sept. 12, the lowest since February 2023. This downward trend will likely continue in response to the Fed&#8217;s decision.
Trending: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
Ian Slater, a New York City-based agent with Compass, noted the real estate community&#8217;s excitement about the rate cut. &#8220;Now that we know the Fed has cut a large amount, 0.5% rather than what some expected to be 0.25%, there is even more exuberance,&#8221; Slater said.
Despite the prevalence of cash purchases in the luxury market, Redfin reports that 44% of luxury home purchases were made with cash in the second quarter. The rate cut is expected to boost market sentiment. Slater predicts &#8220;a continued robust luxury market throughout the remainder of 2024 and potentially even more strength in 2025.&#8221;
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
Lower mortgage rates&#8217; effects on buying power are more striking in high-priced metro areas. In California&#8217;s San Jose metro area, where the median listing price hit $1.4 million in August, a hypothetical drop in mortgage rates to 5.5% could increase buying power by $110,000, according to Realtor.com data cited by Mansion Global.
Matthew Lesser, senior partner at New York City brokerage Leslie Garfield, believes the rate cut will catalyze market activity. &#8220;Historically, this should lead to greater transaction volume and therefore push pricing because of the increased demand,&#8221; Lesser said.
Even for all-cash buyers at the top end of the market, the rate cut has indirect benefits. &#8220;These buyers use leverage in their daily lives, whether for their own businesses or investments,&#8221; Lesser said. Cheaper money will raise consumer confidence and provide greater opportunity to buy more real estate.
Read Next:
<ul>
<li>Mark Cuban believes &#8220;the next wave of revenue generation is around real estate and entertainment&#8221; —<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> this new real estate fund allows you to get started with just $100.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>

Real Estate

44% Of Luxury Homes Bought With Cash – But This 0.5% Fed Rate Cut Could Raise Luxury Home Prices By $110k, Here's How

Piper Sandler analyst Clarke Jeffries upgrades Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) from Neutral to Overweight and raises the price target from $184 to $200.

Upgrades

Price Target

Analyst Ratings

Piper Sandler Upgrades Wix.com to Overweight, Raises Price Target to $200

Piper Sandler analyst Clarke Jeffries downgrades GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) from Overweight to Neutral and raises the price target from $160 to $172.

Downgrades

GDDY

Piper Sandler Downgrades GoDaddy to Neutral, Raises Price Target to $172

GE Aerospace's (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ge#NYSE">GE</a>) 52,000 employee workforce has a powerful new assistant, AI Wingmate, by their side as they work to enhance quality, serve customers, and invent the future of flight.&nbsp;&nbsp;GE Aerospace
GE Aerospace's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) 52,000 employee workforce has a powerful new assistant, AI Wingmate, by their side as they work to enhance quality, serve customers, and invent the future of flight.&nbsp;&nbsp;
GE Aerospace technology leaders worked with one of its key partners in AI development, Microsoft, to use Azure AI, including Azure OpenAI Service, to bring enhanced security, compliance, and responsible AI inside GE Aerospace's own network. Employees now can securely collaborate with AI Wingmate in a human-like back-and-forth conversation on new ideas, new learnings, and new initiatives to propel air travel to new heights.&nbsp;
GE Aerospace employee engagement with the tool has been very strong since its launch in June. To date, the system has received:
<ul>
<li>~500,000 queries, searches, and other employee interactions; and</li>
<li>200,000+ pages processed for different AI chats.&nbsp;</li>
</ul>
"The launch of AI Wingmate will transform employee productivity, allowing our people to spend more time solving our customers' toughest problems," said David Burns, Chief Information Officer, GE Aerospace. "Generative AI is changing the way we all work, enabling us to be more productive with our daily work tasks than ever before. Ultimately, this will strengthen our ability to help the aerospace industry meet our highest objectives of enhanced safety, sustainability, and reducing supply chain constraints."&nbsp;
"Over 60,000 customers spanning industries and countries worldwide are applying the capabilities of Azure AIto deliver tangible results," said Nick Parker, President, Industry &amp; Partner Sales, Microsoft. "We are deeply committed to helping businesses like GE Aerospace implement multimodal AI-powered applications easily and securely. I'm thrilled to see the impact AI is already having at GE Aerospace as the company continues to infuse AI across the company and leverage its power to drive innovation and growth."&nbsp;
AI Wingmate is providing GE Aerospace employees with a secure, internal platform to engage and utilize the full suite of generative AI capabilities and infuse new data and information from employees over time to support the company's business requirements.&nbsp;
"As our workforce continues to become familiar with AI Wingmate, it will become an increasingly more valuable partner over time for GE Aerospace employees," added Burns. "We are particularly excited about plans to launch a new generative AI based module exclusively dedicated to FLIGHT DECK, our proprietary lean operating model that is the foundation of how we work. The generative AI platform will serve as a vehicle for employees to learn about FLIGHT DECK and its ten fundamentals."&nbsp;
&nbsp;
How it works&nbsp;
GE Aerospace employees are using AI Wingmate to enhance their productivity and work experience by having:&nbsp;&nbsp;
<ul>
<li>Instant access to information: Employees can quickly obtain information relevant to their tasks, reducing the time spent searching through documents or waiting for responses from colleagues.&nbsp;</li>
<li>Faster learning and discovery: Employees can use AI Wingmate to perform more advanced searches and queries to support their project work.&nbsp;</li>
<li>More advanced support tools: Employees can use AI Wingmate to draft more tailored communications for specific audiences, rapidly create documents, or ask questions to help understand a complex problem.&nbsp;</li>
</ul>
The launch of this new internal generative AI platform represents a key milestone in GE Aerospace's more than a decade's long journey successfully integrating AI across its business operations. Over this time, GE Aerospace has more than doubled its investment in AI technology, positioning the company as one of the top AI patent holders within the aviation industry.&nbsp;&nbsp;
Today, GE Aerospace is using AI to enhance everything from engine monitoring and part inspections to delivering insights for our airline customers to enable predictive maintenance measures and new ways to optimize fuel efficiency and safety. Click&nbsp;<a href="https://www.geaerospace.com/sites/default/files/ai-fact-sheet.pdf">here</a> to learn more about how GE Aerospace is using AI today and future applications under development.
"The integration of Azure AI platform capabilities including Azure OpenAI Service is delivering a step change in how GE Aerospace employees work and deliver for our customers," said Burns.&nbsp; "AI Wingmate is more than just a smart platform. It's a true catalyst for changing the way we work and what is possible for us to achieve in advancing the future of flight."&nbsp;

MSFT

GE Aerospace Teams Up with Microsoft to Power 52K Workers with AI Wingmate Platform

Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA)))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, TX. The new 12,000 square foot center is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support over 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.
"We are extremely pleased to announce the opening of our new state-of-the-art plasma collection center in Houston," said Amir London, Chief Executive Officer of Kamada. "The opening of this center is an important milestone in Kamada's development and vertical integration, expanding the collection capacity of specialty plasma for our internal use beyond our existing site in Beaumont, TX. The new center in Houston is expected to be one of the largest sites for specialty plasma collection in the U.S. and will also collect normal source plasma to be sold to third parties. We are especially grateful for the skilled and experienced team of plasma collection experts we have hired to lead the development and operations of our new center."
Kamada intends to submit to the FDA a prior approval supplement to Kamada Plasma's existing Biologics License Application (BLA) for the approval of the Houston site, as well as a plasma master file (PMF) to the European Medicines Agency (EMA), during the first half of 2025. The FDA and EMA's regulatory process for obtaining approval for plasma collection centers includes onsite inspection. During the review process, the company is authorized to collect plasma donations at the center. Kamada currently anticipates approval decisions within 9-12 months of submissions.
In addition to the new Houston center, the company has begun construction of its third plasma collection site in San Antonio, TX, which is expected to open during the first half of 2025. Each collection center is expected to contribute annual revenues of $8 million to $10 million in sales of normal source plasma at its full capacity.

Government

Regulations

KMDA

Kamada Expands US Plasma Operations with Houston Center, Plans FDA Submission

Offerings

YOSH

Yoshiharu Global  Filed For Offering Of Up To 400K Shares

Benchmark analyst Daniel Kurnos maintains Sinclair (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) with a Buy and raises the price target from $29 to $30.

SBGI

Benchmark Maintains Buy on Sinclair, Raises Price Target to $30

Leading private markets investment management firm Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) announced that it has been named to the S&amp;P MidCap 400 by S&amp;P Dow Jones Indices, effective before the open of trading today, Monday, September 23, 2024.&nbsp;
For more than 30 years, Hamilton Lane has been dedicated exclusively to private markets investing, providing innovative solutions to institutional and private wealth investors around the world. As of June 30, 2024, the firm had more than $940 billion in assets under management and supervision, composed of nearly $130 billion in discretionary assets – representing 11% year-over-year growth – and more than $810 billion in non-discretionary assets.&nbsp;
Hamilton Lane Co-CEO <a href="https://www.hamiltonlane.com/en-us/about/our-team/erik-hirsch">Erik Hirsch</a> commented: "The addition of our firm to the S&amp;P MidCap 400 Index represents a significant milestone in Hamilton Lane's 33-year growth story – a story that continues to evolve but that has always been driven by our focus on delivering for our clients. &nbsp;We have an exciting path forward, as we continue to lean into our culture of integrity, innovation and the pursuit of excellence, while adapting to meet the evolving needs of private markets investors of all sizes with new technology, new markets and new regions across the globe."

HLNE

Hamilton Lane Joins S&P MidCap 400, Marks Major Growth Milestone in Private Markets

<a href="https://pr.report/2vaa">Alta Global Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) ("Alta" or the "Company"), a pioneering technology company uniting passion and participation in global combat sports with a vision of converting 640 million fans to participants, announced its partnership with <a href="https://pr.report/2vab">UFC Gym Group</a> has the potential to deliver gross revenue of $7,000,000 per annum&#x2A; upon roll-out of UFC Gym's global gym footprint of over 150 gyms. The program will launch in California, scheduled to go on sale to members in September 2024. This represents Alta's first major enterprise partnership and will look to integrate Alta's innovative products and programs across UFC Gym's extensive network of global gyms.
&nbsp;
Nick Langton, Founder and CEO of Alta Global Group, commented, "This partnership with UFC Gym Group is a transformative milestone for Alta. By integrating our Warrior Training Program and mobile marketing platform into UFC Gym's global network, we're poised to significantly expand our reach while offering a unique pathway for UFC fans to experience the sport firsthand. UFC Gym is an ideal partner for us to deliver an unmatched training experience that not only elevates the gyms but also empowers participants. We're excited about the tremendous potential this collaboration holds for driving growth and deepening the connection between 640 million MMA fans and the sport."
Additional highlights of the partnership include:
Program Rollout: Alta will roll out its highly acclaimed 20-week Warrior Training Program across the United States and internationally. In the first year, these programs will be introduced in 15 locations across the US.
Revenue Opportunities: The Alta Warrior Training Program, which averages 24 participants per program, enables gyms to run up to two programs annually. Participants pay between $1,000 and $1,500 for the 20-week experience.
Mobile Marketing Platform: Furthermore, UFC Gym Group will utilize Alta's all-in-one mobile marketing platform, Hype, to enhance customer acquisition and retention across its network of over 150 gyms. Hype, powered by Alta, operates on a traditional Software-as-a-Service (SaaS) model.
Extensive opportunities for growth: Currently, UFC Gym Group boasts over 150 locations in 40 countries worldwide, including 80 in the United States, with hundreds of additional gyms in development.

Alta Global Partners With UFC Gym, Targets $7M Annual Revenue From Global Expansion

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrisaluslifesci.com%2F&amp;esheet=54124814&amp;newsitemid=20240919558761&amp;lan=en-US&amp;anchor=TriSalus+Life+Sciences%26%23174%3B%2C+Inc.&amp;index=1&amp;md5=99cfa17a1abb371957d4eef59928821a">TriSalus Life Sciences&#xAE;, Inc.</a> ("TriSalus" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>), an oncology company integrating its novel delivery technology with standard of care therapies and immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the publication of research titled, "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model," in the peer-reviewed Journal of Vascular and Interventional Radiology. The article illustrates that the PEDD method via the TriNav Infusion System significantly improved delivery of glass microspheres (GM) with deeper penetration into liver tumors and the peritumoral tissue, when compared to delivery of GM with a conventional microcatheter in a transgenic (oncopig) model.
"This is another example of how our PEDD approach effectively tackles a significant challenge in cancer care by ensuring the selective and increased delivery of therapeutics to the tumor. This research advances and validates our understanding of the PEDD method, providing high-resolution evidence of enhanced delivery," said Bryan F. Cox, Ph.D., Chief of Research for TriSalus. "With both proximal and distal placements of the PEDD device, we observed significantly improved delivery of glass microspheres to the tumor, quantified on a millimeter scale. The strength of the proximal infusion data suggests an opportunity to selectively target multiple tumors simultaneously in patients with heavy disease burdens."
"These results contribute to the substantial and expanding body of pre-clinical and clinical evidence supporting the wide-ranging potential applicability of the PEDD approach," said Mary Szela, Chief Executive Officer and President of TriSalus. "Efficient delivery of therapeutics into tumor cells without causing harm to off-target normal tissue remains a real-world challenge in cancer care, and the PEDD approach aims to overcome this obstacle. This publication strengthens our current understanding that, regardless of placement of the technology, either lobar or selective infusions, the PEDD method increased glass microspheres delivery uptake compared to conventional microcatheters. The TriNav device signifies a potential breakthrough in delivering glass microspheres and other drugs into tumors in a highly controlled and targeted manner."
"This study shows the potential of PEDD method to address an unmet need in liver cancer therapy – achieving the same safety profile of selective Y90 treatment to those performed for more advanced diffuse disease using lobar injections. This study suggests that the use of PEDD method alters hemodynamics and the microenvironment in a manner resulting in higher concentrations of microspheres in the tumor compared to the adjacent liver parenchyma, thereby offering the ability to increase efficacy and improve safety. If further validated in human models, this may represent a significant advancement in the management of liver cancer," said Dr. Riad Salem, Chief of Interventional Radiology, and Professor of Radiology, Surgery, and Medicine in Chicago.
The research involved transgenic pigs (oncopigs) with induced liver tumors. These tumors were intra-arterially infused with fluorescently labeled GM. The PEDD method with the TriNav device was compared to the use of conventional microcatheter delivery in both lobar and selective infusions. Near-infrared (near IR) imaging was utilized to detect the GM fluorescent signal in tumors. The results showed significant increases in GM signal intensity in and around tumors after delivery with the PEDD method, with a 117% increase in tumor penetration with lobar infusions and a 39% increase with selective infusions compared to conventional delivery. Lobar PEDD delivery of GM to the tumor was statistically equivalent to conventional selective delivery (p=0.497).

TLSI

TriSalus PEDD Method Increases Microsphere Penetration in Liver Tumors, Study Highlights New Delivery Approach

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Progyny Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>)</h3>
<ul>
<li>On Sept. 19, the company said a client elected to exercise an option to terminate its services agreement with the company. The company's stock fell around 32% over the past five days and has a <a href="https://www.benzinga.com/quote/PGNY">52-week low of $13.93</a>.</li>
<li>RSI Value: 26.50</li>
<li>PGNY Price Action: Shares of Progyny rose 1% to close at $16.62 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"> latest PGNY news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="895" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171.png" alt="" class="wp-image-560811" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071143/image-171-768x721.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<h3 class="wp-block-heading">Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Sept. 4, Indivior issued an update on Aelis Farma&#8217;s Phase 2B study with AEF0117 in participants with cannabis use disorder. It <a href="https://www.benzinga.com/quote/INDV">has a 52-week low</a> of $9.14.</li>
<li>RSI Value: 25.92</li>
<li>RELI Price Action: Shares of Indivior fell 2.1% to close at $9.48 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"> trend in INDV stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172.png" alt="" class="wp-image-560812" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071157/image-172-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</h3>
<ul>
<li>On Sept. 17, Moderna announced that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older.The vaccine targets the KP.2 variant of COVID-19. The company plans to begin delivery of the vaccine to the Public Health Agency of Canada shortly. "With the recent increase in COVID-19-infections, staying up to date with your COVID-19 vaccination remains one of the best ways to help protect yourself from severe illness," said Dr. Shehzad Iqbal, country medical director, Moderna Canada. The company's shares fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/MRNA">low of $62.55</a>.</li>
<li>RSI Value: 28.17</li>
<li>MRNA Price Action: Shares of Moderna fell 3.4% to close at $65.69 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1">breakout in MRNA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173.png" alt="" class="wp-image-560813" style="width:610px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23071229/image-173-768x710.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
Read Next:<a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Long Ideas

INDV

MRNA

PGNY

Top 3 Health Care Stocks That May Explode This Month

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Forthofix.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=Orthofix+Medical+Inc&amp;index=1&amp;md5=f980520f95bd1a9234c20487cdf8b284">Orthofix Medical Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix's proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbonegrowththerapy.com%2Ftherapies%2Fspinal-fusion%2Fspinalstim-lumbar-fusion%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=SpinalStim&amp;index=2&amp;md5=c26f0cc0fb348022b3ce0b675596e790">SpinalStim</a>&#x2122; bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.
The abstract will be presented by Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, on September 25, during the Research and Innovation Showcase in the McCormick Place West Lobby of the McCormick Convention Center.
During the NASS annual meeting, Orthofix is also highlighting a variety of new products including the full market launch of OsteoStrand&#x2122; Plus C. A 100% bone-derived graft, OsteoStrand Plus C is comprised of Demineralized Bone Matrix (DBM) fibers and Accell&#x2122; Bone Matrix, a dispersed form of DBM that provides immediate release of growth factors upon implantation and increases the concentration of growth factors in the product, and cancellous chips. Used as a bone graft material in fusion applications, the OsteoStrand Plus C features improved graft packability relative to non-chip containing options – for a denser fill and to ensure minimal graft displacement. Additionally, Orthofix is announcing the launch of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fm6disc.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=M6-C&amp;index=3&amp;md5=0f2300dfde3b2d3c8390c084ccf90edc">M6-C</a>&#x2122; Single-Use, Disposable Instrumentation sets, the first FDA-cleared, single-use, disposable instruments designed specifically for cervical disc arthroplasty.

OFIX

Orthofix Unveils New Spinal Fusion Products and Data, Highlighting Innovation at NASS Annual Meeting

Alibaba Group Holding&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) cloud computing services unit tapped&nbsp;Nvidia&nbsp;Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to boost the&nbsp;autonomous driving&nbsp;experience for Chinese smart vehicle owners like Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>),&nbsp;Great Wall Motor Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GWLLY#OTC">GWLLY</a>),&nbsp;Geely Auto&#8217;s&nbsp;ZEEKR Intelligent Technology Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)&nbsp;and the EV unit of&nbsp;Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>).
China is currently grappling with U.S. advanced semiconductor sanctions, which have restricted its access to Nvidia and other chipmakers&#8217; sophisticated artificial intelligence chips.
The U.S. chip companies opposed the U.S. move, citing the importance of China as a key semiconductor market. Alibaba has also voiced how the embargo has affected its AI endeavors.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/09/40923879/chinas-ymtc-makes-strides-in-chip-production-substitutes-asml-lam-research-tech-as-us-sanctions-bite" rel="noreferrer noopener">China&#8217;s YMTC Makes Strides in Chip Production; Substitutes ASML, Lam Research Tech As US Sanctions Bite: Report</a>
Alibaba Cloud showcased a large multimodal model (LMM) solution for automotive applications that it co-developed with its intelligent cockpit solution provider Banma Network Technology and Nvidia at the&nbsp;Apsara Conference, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3279428/alibaba-nvidia-collaborate-advanced-autonomous-driving-solution-computing-services" rel="noreferrer noopener">reports</a>.
Alibaba Cloud integrated Qwen&#8217;s portfolio of proprietary large language models (LLMs) with Nvidia&#8217;s Drive AGX Orin platform for autonomous vehicles. The new LMM solution will enable in-car voice assistants to offer recommendations, and execute voice commands SCMP cites Alibaba Cloud.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17.png" alt="" class="wp-image-560553" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23042244/newplot-17-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Nvidia and Alibaba Cloud look to Qwen LLMs to Nvidia&#8217;s Drive Thor, a centralized car computing platform.
Last week, Alibaba kicked off its <a target="_blank" href="https://www.benzinga.com/government/24/09/40936014/whats-going-on-with-chinese-tech-stocks-like-alibaba-pdd-on-thursday" rel="noreferrer noopener">Aspara Conference 2024</a>, showcasing 100 open-source AI models catering to applications and sectors ranging from automobiles to gaming and science research.
Chinese e-commerce juggernaut Alibaba Group Holding&#8217;s stock has risen over 1% in the last 12 months as the weak domestic economy and geopolitical tensions bite.
Investors can gain exposure to the stock through the Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) and the Trust for Professional Managers ActivePassive International Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APIE#NYSE">APIE</a>).
Price Actions: BABA stock is up 0.85% at $89.04 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40918150/alibaba-strikes-5-year-cloud-deal-with-indonesias-goto-delays-stake-divestment" target="_blank" rel="noreferrer noopener">Alibaba Strikes 5-Year Cloud Deal with Indonesia&#8217;s GoTo, Delays Stake Divestment</a></li>
</ul>
Photo by Fooksou Lamimo via Wikimedia Commons

Emerging Markets

Tech

Media

APIE

BABA

GWLLY

NVDA

PowerShares Golden Dragon Halter USX China Portfolio

XIACY

Alibaba Teams Up With Nvidia to Supercharge EVs for Chinese Automakers: Report

RBC Capital analyst Gregory Renza initiates coverage on CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Outperform rating and announces Price Target of $66.

Initiation

CGON

RBC Capital Initiates Coverage On CG Oncology with Outperform Rating, Announces Price Target of $66

<a href="https://www.globenewswire.com/Tracker?data=fTnauvHXrBinpqMkcNrU2jXyFxKpy_arXJzy_b5ASWO6l7AzfHZmmBhfNJU82qOIF0IRqYDITjpbTjTmYaz8lg==">uniQure</a> N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AMT-191, uniQure's investigational gene therapy for the treatment of Fabry disease, a rare, inherited genetic disease. In August 2024, uniQure announced the dosing of the first patient in its U.S., multi-center, open-label Phase I/IIa trial of AMT-191.
"This important designation highlights the need for new gene therapies like AMT-191 for patients with Fabry disease with the potential of delivering meaningful benefit given the suboptimal effectiveness of current chronic treatments," stated <a href="https://www.globenewswire.com/Tracker?data=XJHujD0zFsqCKj2AQYLx5YZE0M2jd1UjijpyNswg3uU3SriFCvwWI96vkEi8AA3le2sz_K36hMQhw9mjNc65v089QNwHSlUPjRhS5ybbM0ZoWv13dGsruJHJU5iG2D1r51IROOb0I1SREI2dhF2Cck4rSdmcC2GyFO4ZLtacqF9PhX4xHMVg625XkJYrftYl">Walid Abi-Saab, M.D., chief medical officer of uniQure</a>. "This designation supports our Phase I/IIa clinical trial and we look forward to rapidly generating clinical proof-of-concept data and providing initial data in 2025."
In patients with Fabry disease, a pathogenic variant in the galactosidase alpha (GLA) gene leads to α-galactosidase A (aGAL-A) enzyme deficiency, which in turn results in a progressive accumulation of lipids in multiple cell types, including kidney and heart cells, eventually resulting in a multi-system disorder. AMT-191 is a one-time intravenously administered investigational AAV5-based gene therapy that uses a proprietary, highly potent promoter to deliver a GLA transgene designed to target the liver to produce GLA protein.
The Phase I/IIa clinical trial of AMT-191 will be conducted in the United States. The multicenter, open-label trial consists of two cohorts with up to six adult male patients each: a low-dose cohort of 6x1013 gc/kg and a high-dose cohort of 3x1014 gc/kg delivered through a one-time intravenous infusion. Patients will continue to receive their regular enzyme replacement therapy until the criteria for withdrawal is met and will be followed for a period of 24 months. The trial will explore the safety, tolerability, and early signs of efficacy by measuring the expression of lysosomal enzyme aGLA-A. Additional details are available on <a href="https://www.globenewswire.com/Tracker?data=7KolP2h89egUHI8jH_Zo5bdDQZFzZM_38LjWTPDf3Kdw9gSQKRHs9DeKDUPU-daOSt9uPtk10WEjZA6W4qStkajilCQxvaD3HJzRrulXR-o=">www.clinicaltrials.gov</a> (NCT06270316).
The FDA's Orphan Drug Designation provides a special status for investigational drugs being developed for rare diseases considered to affect only up to 200,000 people in the United States. Orphan drug status provides certain incentives, including tax credits, grants and waiver of certain administrative fees for clinical trials as well as seven years of market exclusivity in the United States following drug approval.

QURE

FDA Grants Orphan Drug Status to uniQure's AMT-191, Aiming to Treat Fabry Disease

Biotech

Health Care

Stock Split

General

Orgenesis Approves A 1-for-10 Reverse Stock Split Effective At 5:00 Pm Eastern Time On September 24

MIND Technology, Inc. ("MIND" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) announced today that its Seamap unit has received an order for a GunLink source controller amounting to approximately $5.1 million.&nbsp; Subsequent to July 31, 2024, the Company has received orders totaling approximately $7.9 million.
Mark Welker, Vice President of MIND and Seamap Managing Director, stated, "We are seeing strong demand for our GunLink source controllers. These most recent orders indicate the continuing demand across our family of source controller products. We expect to deliver a portion of these orders in this fiscal year; however, the majority will be delivered in our next fiscal year.&nbsp; In addition to the orders that we have in hand, we are pursuing a number of significant opportunities that we expect to bring to fruition in the coming weeks and months. We think our continuing backlog and pipeline of business bodes well for the balance of this fiscal year and next year as well."

MIND

MIND Technology's Seamap Unit Secures $5.1M GunLink Order, Expands Total to $7.9M

SKYE

Skye Bioscience Comments Regarding A Recent Announcement By Novo Nordisk On Phase 2a Topline Data With Monlunabant And, Reiterates Confidence In Its Nimacimab Clinical Development Plan, Says 16-week Top-line Weight Loss Data Validates Mechanism Of Action Targeting Peripheral CB1 Receptors

Federal Reserve

Minneapolis Fed President Kashkari Said Balance Of Risks Have Shifted Toward Risk Of Further Labor Market Weakening, Higher Unemployment; 50 BPS Rate Cut Was Right Decision, Reflects Progress On Inflation, Softening Of Labor Market

Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today provided detailed virology data supporting previously communicated neutralization activity results, along with a genetic and structural analysis of past and present SARS-CoV-2 variant spike proteins, including the established molecular target of pemivibart.
As part of Invivyd's ongoing monitoring of antiviral activity, Invivyd contracts with LabCorp's Monogram Biosciences lab to provide independent, robust virology assessments in a consistent lineal chain that allows for consideration of potential changing pemivibart potency as SARS-CoV-2 evolves. Pemivibart potency against contemporary viruses KP.3.1.1 and LB.1 remains in-line with the totality of predominant variants dating back to 2022, including isolates identified during the conduct of the CANOPY Phase 3 clinical trial from late 2023 to early 2024. Data Table 1, below, provides relevant comparative values drawn from the PEMGARDA Healthcare Providers Fact Sheet.
"Quantitative neutralization assays exhibit marked intrinsic variability. Since discovery, pemivibart has exhibited impressively stable neutralization results across a wide range of SARS-CoV-2 variants, including and through contemporary variants tested," said Robert Allen, Ph.D., Chief Scientific Officer of Invivyd. "The values we observe thus far generally fall within the expected variability of the assay systems we employ."&nbsp;&nbsp;
Invivyd also provided an update to ongoing structural analysis showing no meaningful mutational change in the pemivibart binding site since the Omicron shift late in 2021. These data are presented in Figure 1 below. The pemivibart binding site is defined as a region of amino acid residues on the spike protein within 5 angstroms (5 Å) of the interaction between pemivibart and spike protein in a crystal structure and consists of 19 key amino acids. Invivyd's ongoing genetic and structural analyses of these residues provide the underlying biological rationale for the company's ongoing expectation for neutralization activity of pemivibart in the face of constant and convergent mutation in the SARS-CoV-2 spike protein. Analysis to date of all 19 amino acids presented below shows de minimis mutational change with ongoing stability to the binding site since the Omicron shift.
"To stay ahead of the curve, it is necessary to integrate data across multiple sources, including clinical and wastewater surveillance, as well as functional genomics. Invivyd's work over the last few years has achieved exactly that," said Kristian Andersen, Ph.D., a professor in the Department of Immunology and Microbiology at Scripps Research and member of Invivyd's scientific advisory board. "Continued surveillance of SARS-CoV-2 evolution is critically important to ensure that we can effectively counter the threat posed by the virus."

IVVD

Invivyd Shares New Data on Pemivibart's Neutralization of COVID Variants, Details Virus Evolution

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ascent Solar (NASDAQ:<a href="https://investorplace.com/stock-quotes/asti-stock-quote/">ASTI</a>) stock is up on Friday after the solar technology company announced the <a href="https://finance.yahoo.com/news/ascent-solar-technologies-announces-debt-120000575.html">payoff of its debts</a>.



This is in connection to convertible notes that were issued to institutional investors on Dec. 19, 2022. Ascent Solar says that it has completely paid off the remaining institutional investor&rsquo;s notes.



According to Ascent Solar, this covers all of the liabilities it has to this investor under that equity agreement. As such, the company says that it no longer has any obligations remaining from that agreement.



<h2>What This Means for ASTI Stock</h2>



With the paying off of these debts, Ascent Solar puts itself in a much better financial position. That&rsquo;s good news for the company and investors in ASTI stock. It&rsquo;s likely this is boosting the morale of investors in the company today.



With today&rsquo;s news also comes heavy trading of ASTI stock as investors buy the shares. This has more than 104 million shares of ASTI changing hands as of this writing. That&rsquo;s well above its daily average trading volume of about 22 million shares.



ASTI stock is up 11.4% as of Friday morning. However, the shares are still down 85.8% since the start of the year.



Investors who are seeking out even more of the most recent stock market stories are in luck!



We have all of the hottest stock market news traders need to know about on Friday! A few examples include what&rsquo;s going on with shares of 36Kr&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>), Chipotle&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/cmg-stock-quote/">CMG</a>) and Sarepta Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/">SRPT</a>) stock this morning. You can catch up on all of these matters at the following links!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-36kr-krkr-stock-up-17-today/">Why Is 36Kr (KRKR) Stock Up 17% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/dear-chipotle-cmg-stock-fans-mark-your-calendars-for-june-25/">Dear Chipotle (CMG) Stock Fans, Mark Your Calendars for June 25</a></li>



<li><a href="https://investorplace.com/2024/06/sarepta-therapeutics-srpt-stock-surges-30-on-giant-fda-boost/">Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-ascent-solar-asti-stock-up-11-today/">Why Is Ascent Solar (ASTI) Stock Up 11% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Ascent Solar (ASTI) Stock Up 11% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
36Kr (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) stock is up on Friday after the Chinese content creation company <a href="https://finance.yahoo.com/news/36kr-enters-strategic-partnership-sensetime-113000664.html">announced a new partnership</a> with SenseTime (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SNTMF#OTC">SNTMF</a>).



SenseTime is an artificial intelligence (<a href="https://investorplace.com/stock-quotes/ai-stock-quote/">AI</a>) company with a focus on Artificial General Intelligence. That includes the ability to bring AI services to content creation and media businesses.



With this partnership, 36Kr will make use of SenseTime&rsquo;s SenseChat and SenseMirage. These will upgrade its content production model while helping to lower the cost of media creation.



With this partnership, 36Kr has announced plans for new offerings that take advantage of this AI. That includes AI Media Coverage, AI Financial Report Interpretation and more product services.



36Kr co-chairman and CEO Dagang Feng said the following about the partnership.




&ldquo;Our strategic partnership with SenseTime once again demonstrates 36Kr&rsquo;s acumen in frontier technology and foresight for innovation. In collaboration with SenseTime, we will continuously explore multi-scenario applications of AGI technology to integrate large-scale AI model technologies into the media industry, enhancing our content production capabilities and commercialization efficiency.&rdquo;




<h2>KRKR Stock Movement Today</h2>



With this news comes heavy trading of KRKR stock on Friday. Tha thas more than 66 million shares changing hands. This is well above its daily average trading volume of about 55,000 shares.



KRKR stock is up 16.6% as of Friday morning. However, the shares are still down 32.2% year-to-date.



Investors looking for more of the most recent stock market stories are in luck!



We have all of the hottest stock market news traders need to know about on Friday! Among that is what has shares of Chipotle&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/cmg-stock-quote/">CMG</a>), Sarepta Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/">SRPT</a>) and Professional Diversity&nbsp;Network&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock in the news today. All of that info is ready at the following links!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/dear-chipotle-cmg-stock-fans-mark-your-calendars-for-june-25/">Dear Chipotle (CMG) Stock Fans, Mark Your Calendars for June 25</a></li>



<li><a href="https://investorplace.com/2024/06/sarepta-therapeutics-srpt-stock-surges-30-on-giant-fda-boost/">Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-professional-diversity-network-ipdn-stock-down-22-today/">Why Is Professional Diversity Network (IPDN) Stock Down 22% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-36kr-krkr-stock-up-17-today/">Why Is 36Kr (KRKR) Stock Up 17% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is 36Kr (KRKR) Stock Up 17% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning!



Moving stocks today are a new patent, new agreements, delisting news, a proposed public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Agrify (NASDAQ:<a href="https://investorplace.com/stock-quotes/agfy-stock-quote/">AGFY</a>) stock is rocketing more than 56% alongside heavy pre-market trading.</li>



<li>Sunrise New Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/epow-stock-quote/">EPOW</a>) shares are soaring over 36% after being <a href="https://www.nasdaq.com/press-release/sunrise-new-energys-lithium-ion-battery-patent-granted-key-funding-guizhou-province">granted a new battery patent funding</a>.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) stock is surging close to 32% without any clear news this morning.</li>



<li>Roadzen (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdzn-stock-quote/">RDZN</a>) shares are gaining more than 27% with heavy early morning trading today.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is increasing over 23% despite a lack of news this morning.</li>



<li>Delta Apparel (NYSEMKT:<a href="https://investorplace.com/stock-quotes/dla-stock-quote/">DLA</a>) shares are heading more than 19% higher on Monday morning.</li>



<li>Unusual Machines (NYSEMKT:<a href="https://investorplace.com/stock-quotes/umac-stock-quote/">UMAC</a>) stock is rising 19% <a href="https://www.nasdaq.com/press-release/correction-source-unusual-machines-selected-provide-first-drone-red-cats-fangtm-line">on a drone agreement</a>.</li>



<li>Bitcoin Depot (NASDAQ:<a href="https://investorplace.com/stock-quotes/btm-stock-quote/">BTM</a>) shares are climbing over 15% this morning.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is jumping 15% on a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-holdings-limited-announces-launch-new-investment-relationship">new investment relationship</a>.</li>



<li>Denali Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/deca-stock-quote/">DECA</a>) shares are up more than 14% on Monday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>BitFuFu (NASDAQ:<a href="https://investorplace.com/stock-quotes/fufu-stock-quote/">FUFU</a>) stock is diving over 27% after a major rally on Friday.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are tumbling more than 25% ahead of its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318404814&amp;type=PDF&amp;symbol=DMTK&amp;cdn=2f95604b7d0b2db1ef0d52c1cc04ae14&amp;companyName=DermTech+Inc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">delisting later this week</a>.</li>



<li>American Rebel (NASDAQ:<a href="https://investorplace.com/stock-quotes/areb-stock-quote/">AREB</a>) stock is taking a 25% beating <a href="https://www.nasdaq.com/press-release/american-rebel-signs-distribution-agreement-dichello-distributors-state-connecticut">following a Friday rally</a>.</li>



<li>36KR (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares are retreating over 17% after jumping in the <a href="https://investorplace.com/2024/06/why-is-36kr-krkr-stock-up-17-today/">previous day of trading</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is sliding more than 17% as it <a href="https://investorplace.com/2024/06/why-is-professional-diversity-network-ipdn-stock-down-22-today/">continues negative movement</a>.</li>



<li>G1 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) shares are falling nearly 17% alongside a <a href="https://www.nasdaq.com/press-release/g1-therapeutics-provides-update-phase-3-preserve-2-trial-patients-receiving">Phase 3 clinical trial update</a>.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock is dropping over 16% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318408657&amp;type=PDF&amp;symbol=ALLR&amp;cdn=2b98061f2188998b482fa6052ee2392c&amp;companyName=Allarity+Therapeutics+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-06-21">shareholder meeting plans</a>.</li>



<li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) shares are decreasing more than 14% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318408996&amp;type=PDF&amp;symbol=SPEC&amp;cdn=3890204bdd59982142fb7ff1035bfa7b&amp;companyName=Spectaire+Holdings+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-06-21">proposed public offering</a>.</li>



<li>Inuvo (NYSEMKT:<a href="https://investorplace.com/stock-quotes/inuv-stock-quote/">INUV</a>) stock is slipping over 14% today.</li>



<li>Molecular Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/moln-stock-quote/">MOLN</a>) shares close out our pre-market stock movers down more than 13% this morning.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-june-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!



Moving stocks this morning are earnings reports, insider buying, offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is rocketing more than 78% alongside heavy pre-market trading.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are soaring over 47% with strong early morning trading.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is surging more than 39% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318411360&amp;type=PDF&amp;symbol=GLYC&amp;cdn=8f7645b9da4ce31c36360d7737c007dc&amp;companyName=GlycoMimetics+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-06-24">alongside insider buying</a>.</li>



<li>Anew Medical (OTCMKTS:<a href="https://investorplace.com/stock-quotes/leas-stock-quote/">LEAS</a>) shares are gaining over 38% without any clear news this morning.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) shares are increasing more than 24% with strong pre-market trading.</li>



<li>Regis (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgs-stock-quote/">RGS</a>) stock is rising over 21% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318412499&amp;type=PDF&amp;symbol=RGS&amp;cdn=4f01bbb678bba4ddafaac79f77ec0544&amp;companyName=Regis+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-25">senior secured credit facility</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are heading close to 20% higher with heavy pre-market trading today.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is jumping more than 17% <a href="https://www.nasdaq.com/press-release/kaival-brands-announces-closing-60-million-public-offering-2024-06-24">after closing a public offering</a>.</li>



<li>BioXcel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/btai-stock-quote/">BTAI</a>) shares are climbing over 13% on <a href="https://www.nasdaq.com/press-release/bioxcel-therapeutics-announces-positive-topline-results-post-marketing-requirement">topline results from a study</a>.</li>



<li>Captivision (NASDAQ:<a href="https://investorplace.com/stock-quotes/capt-stock-quote/">CAPT</a>) stock is up more than 12% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is plummeting over 25% on plans for a <a href="https://finance.yahoo.com/news/faraday-future-announces-plans-regaining-215900667.html">reverse stock split</a>.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) shares are diving more than 22% after a massive rally yesterday.</li>



<li>Beyond Air (NASDAQ:<a href="https://investorplace.com/stock-quotes/xair-stock-quote/">XAIR</a>) stock is tumbling over 19% on <a href="https://finance.yahoo.com/news/beyond-air-inc-xair-reports-212503389.html">lackluster Q4 earnings</a>.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) shares are retreating more than 19% <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-113-today/">after rallying yesterday</a>.</li>



<li>SolarEdge Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sedg-stock-quote/">SEDG</a>) stock is taking an over 16% beating on a <a href="https://www.nasdaq.com/press-release/solaredge-technologies-inc-announces-proposed-private-offering-300-million">$300 million private offering</a>.</li>



<li>IGC Pharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/igc-stock-quote/">IGC</a>) shares are dropping more than 16% on its <a href="https://www.nasdaq.com/press-release/igc-reports-financial-results-fiscal-year-ended-march-31-2024-2024-06-24">latest earnings report</a>.</li>



<li>Oragenics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ogen-stock-quote/">OGEN</a>) stock is falling over 15% on a <a href="https://www.stocktitan.net/news/OGEN/oragenics-inc-announces-proposed-public-688vwqnwez4o.html">proposed public offering</a>.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are decreasing nearly 12% after a <a href="https://www.nasdaq.com/press-release/dermtech-files-voluntary-chapter-11-protection-2024-06-18">recent bankruptcy filing</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is slipping more than 11% with recent weakness.</li>



<li>36KR (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

36Kr partners with Zhi-Tech Group to expand business

36Kr Holdings Inc (KRKR) has released an update. 36Kr Holdings Inc. has announced a significant shift in its management team, with Ms. Lin Wei step...

36Kr Holdings Inc. Appoints New CFO

36Kr Holdings GAAP EPADS of -$0.31, revenue of $14.09M

36Kr Holdings Inc (KRKR) has released an update. 36Kr Holdings Inc., a leading New Economy platform in China, has reported a 9.2% increase in its f...

36Kr Holdings Inc. Navigates Economic Challenges

36Kr Holdings Inc. (KRKR) Q2 2024 Earnings Call Transcript

36Kr Holdings Inc (KRKR) has released an update. 36Kr Holdings Inc., a key player in China's New Economy sector, has announced a plan to modify its...

36Kr Holdings Inc. Announces ADS Ratio Change

AGFY

ALLR

ASTI

BTAI

CAPT

COOT

DECA

EPOW

FFIE

FUFU

GLYC

GTHX

INUV

LEAS

MLGO

NCPL

NUKK

OGEN

RDZN

SEDG

SNTI

SNTMF

UMAC

VLCN

XAIR

Press Releases

36Kr Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on Thursday, March 28, 2024

Earnings

36Kr Holdings Inc. Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

36Kr Holdings Inc. Files 2023 Annual Report on Form 20-F

36Kr Hosts "AI Partner • Advanced Productivity" Conference

Contracts

36Kr Enters into Strategic Partnership with SenseTime to Pioneer AGI Innovation

Virtual Production Market Set for Significant Expansion Driven by Technological Innovations & Shifts in Media Consumption Habits

36Kr Partners with Consumer Tech Expert Zhi-Tech Group to Drive Business Expansion

Management

36Kr Holdings Inc. Announces Changes to Management and Board of Directors

36Kr Holdings Inc. to Report 2024 First Half Financial Results on Tuesday, September 3, 2024

36Kr Holdings Inc. Reports Unaudited Financial Results for the First Half of 2024

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

36KR Holdings

36KR Holdings (KRKR) Forecast

36KR Holdings (NASDAQ:KRKR) Stock, Quote.Headers.trade-ideas